- |||||||||| moxidectin / Generic mfg., ivermectin oral / Generic mfg.
Journal: Macrofilaricidal Activity, Acute and Biochemical Effects of Three Lichen Species Found on Mount Cameroon. (Pubmed Central) - Jan 18, 2022 Ivermectin and recently moxidectin are the only drugs approved for clinical management of the disease, both of which have several limitations...These two most active extracts had no significant effect on liver enzymes, alanine aminotransferase, and aspartate (P values < 0.05), but a high AST : ALT ratio (2.59) for Pam indicates likely reversible adverse hepatic toxicity. The high macrofilaricidal activity and selectivity of P. tinctorum suggest it is a potential source of new macrofilaricides which should be further investigated to identify its bioactive constituents.
- |||||||||| ivermectin oral / Generic mfg.
Review, Journal: CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target. (Pubmed Central) - Jan 15, 2022 Despite lesser affinity towards COVID-19 virus, as compared to ACE2, this receptor provides a suitable justification behind elevated blood glucose levels in infected patients, retarded COVID-19 risk in women, enhanced susceptibility in geriatrics, greater infection susceptibility of T cells, infection prevalence in non-susceptible human cardiac pericytes and so on. The manuscript invokes the title role and distribution of CD147 in COVID-19 as an entry receptor and mediator of endocytosis-promoted entry of the virus, along with the "catch and clump" hypothesis, thereby presenting its Fundamental significance as a therapeutic target for potential candidates, such as Azithromycin, melatonin, statins, beta adrenergic blockers, ivermectin, Meplazumab etc. Thus, the authors provide a comprehensive review of a different perspective in COVID-19 infection, aiming to aid the researchers and virologists in considering all aspects of viral entry, in order to develop a sustainable and potential cure for the 2019 COVID-19 disease.
- |||||||||| ivermectin oral / Generic mfg.
Retrospective data, Journal: Management of common scabies and postscabetic itch in adults: Lessons learned from a single-center retrospective cohort study. (Pubmed Central) - Jan 15, 2022 More participants in the older (mean: 55 years; standard deviation: 21 years; p = .002) combined treatment group experienced postscabetic itch than in the younger (mean: 42 years; standard deviation: 19 years) permethrin-only treatment group (42% vs. 25%; p = .072). These findings support the use of combined topical permethrin plus oral ivermectin therapy in treating common scabies, highlight that postscabetic itch can persist for longer than previously reported, and reveal a potential relationship between older age and postscabetic itch.
- |||||||||| hydroxychloroquine / Generic mfg., ivermectin oral / Generic mfg.
Journal: Pharmaceutical messianism and the COVID-19 pandemic. (Pubmed Central) - Jan 14, 2022 Demonstrating the analytic value of our framework, we present three case studies, constructed using academic and journalistic sources, during the COVID-19 pandemic: hydroxychloroquine in France, ivermectin in the Philippines, and Covid-Organics in Madagascar. We conclude by identifying some implications of our findings on public health and avenues for future research.
|